CIV H3N8 was already an emerging concern within the veterinary community when the highly contagious CIV type H3N2 was identified in the U.S. in March 2015 and quickly spread across 39 states.1,2 In response to this outbreak, Zoetis was the first to offer a vaccine to protect dogs against H3N2.
CIV is highly contagious and can be difficult to diagnose and potentially difficult to treat. Prevention against both types of CIV remains the best course of action to reduce the risk of outbreaks and develop herd immunity within your community.
A number of diagnostic challenges and quarantine requirements underline the advantages of vaccination:
- Clinical signs do not emerge until after the majority of virus shedding has occurred.
- Samples collected during clinical exams may not identify CIV due to in intermittent and short duration of viral shedding.3
- Virtually all dogs exposed to canine influenza virus become infected.2
- CIV may be associated with other infections as part of Canine Infectious Respiratory Disease (CIRD).
- In some cases, symptoms can be severe, including moderate nasal discharge, coughing, sneezing, depression, retching, labored breathing and fever (>39.5 C).
- Dogs infected with CIV H3N2 may require an extended isolation period.4
Risk Implications for Clinics
Regardless of quality of care, outbreaks of CIV can lead to severe consequences for practices:
- Damage to the hospital's reputation.
- Need for suspension of services such as boarding, daycare and grooming.
- Intensive decontamination protocols.
- Diversion of healthy patients to other practices.